Company: NIVFW
Filing Date: 2025-10-31
Form Type: 424B3
Source: 0001213900-25-104469
Chunk: 148

Company: NewGenIvf Group Ltd
Filing Date: 2025-10-31
Form: 424B3
Chunk 148
---
 or too few chromosomes) in a developing embryo. PGS improves success rates of in vitro fertilization   
 by ensuring the transfer of euploid embryos that have a higher chance of implantation and resulting in a live birth. PGS has improved 
 clinical outcomes for NewGenIvf by achieving a higher implantation rate of 70.9% and reducing miscarriage rates by 26.6%.             |

| ● | Next-Generation Sequencing                                                                                                             
 (“NGS”): NGS is a high-throughput technology for determining the sequence of deoxyribonucleic acid (“DNA”)                             
 or ribonucleic acid (“RNA”) to study genetic variation associated with diseases or other biological phenomena. NGS determines          
 the sequence of a sample all at once by using parallel sequencing. Traditional Sanger sequencing determines the sequence of a sample   
 one section at a time. Sequencing thousands of gene fragments simultaneously with NGS reduces time and cost associated with sequencing 
 and increases the coverage quality and data output.                                                                                    |

| ● | Preimplantation Genetic                                                                                                                   
 Diagnosis (“PGD”): Similar to PGS, PGD is also used in parallel with an IVF treatment cycle. But PGD is a process                         
 more enhanced than PGS since it scans for individual genes. PGD is the practice of evaluating embryos for specific genetic abnormalities, 
 such as sickle cell disease or cystic fibrosis, where carrier status has been documented in each of the parents. By using this technique, 
 physicians are able to check the genes or chromosomes for a specific genetic condition. PGD can decrease the risk of miscarriage          
 and this technology can help women better achieve a healthy pregnancy. Individuals who suspect or know they carry genes for serious       
 medical conditions may opt to screen for healthy embryos ahead of time.                                                                   |

<div align='center'>83</div>

Well Established Brand with Reliable Reputation

The founders of NewGenIvf
entered the fertility market as agents in 2011 by introducing patients in need to a Thailand clinic for fertility treatments. The founders
of NewGenIvf started to operate their own clinic in Thailand in 2014 and subsequently added clinics in Cambodia and Kyrgyzstan. Since
then, NewGenIvf has attracted clients from countries throughout Asia-Pacific, including Mainland China, Hong Kong, India, Thailand,
Australia and Taiwan.

NewGenIvf benefits from the
favourable geographic locations of its clinics, especially its clinic in Thailand. Located in central Bangkok and situated in one of